ECSP23095204A - Composiciones y métodos para mejorar la función visual - Google Patents
Composiciones y métodos para mejorar la función visualInfo
- Publication number
- ECSP23095204A ECSP23095204A ECSENADI202395204A ECDI202395204A ECSP23095204A EC SP23095204 A ECSP23095204 A EC SP23095204A EC SENADI202395204 A ECSENADI202395204 A EC SENADI202395204A EC DI202395204 A ECDI202395204 A EC DI202395204A EC SP23095204 A ECSP23095204 A EC SP23095204A
- Authority
- EC
- Ecuador
- Prior art keywords
- visual function
- methods
- individual
- compositions
- improve visual
- Prior art date
Links
- 230000004382 visual function Effects 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 230000002207 retinal effect Effects 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14145—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14151—Methods of production or purification of viral material
- C12N2750/14152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Ophthalmology & Optometry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Dental Preparations (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente revelación presenta composiciones y métodos para restaurar o mejorar la función visual en un individuo mediante la administración a dicho individuo de una composición farmacéutica que comprende un vector viral adenoasociado recombinante (rAAV) que tiene una secuencia de polinucleótidos que codifica una opsina de cono de longitud de onda media (MWopsina). La MWopsina se expresa en una célula de la retina en el individuo, restaurando o mejorando así la función visual.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163191525P | 2021-05-21 | 2021-05-21 | |
US202163292746P | 2021-12-22 | 2021-12-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP23095204A true ECSP23095204A (es) | 2024-01-31 |
Family
ID=81928130
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ECSENADI202395204A ECSP23095204A (es) | 2021-05-21 | 2023-12-19 | Composiciones y métodos para mejorar la función visual |
Country Status (15)
Country | Link |
---|---|
US (1) | US20230049217A1 (es) |
EP (1) | EP4341412A1 (es) |
JP (1) | JP2024522072A (es) |
KR (1) | KR20240010489A (es) |
AU (1) | AU2022278028A1 (es) |
CA (1) | CA3218689A1 (es) |
CO (1) | CO2023017779A2 (es) |
CR (1) | CR20230599A (es) |
DO (1) | DOP2023000255A (es) |
EC (1) | ECSP23095204A (es) |
IL (1) | IL308027A (es) |
PE (1) | PE20240137A1 (es) |
TW (1) | TW202313981A (es) |
UY (1) | UY39772A (es) |
WO (1) | WO2022243913A1 (es) |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL105914A0 (en) | 1992-06-04 | 1993-10-20 | Univ California | Methods and compositions for in vivo gene therapy |
USH2191H1 (en) * | 2000-10-24 | 2007-06-05 | Snp Consortium | Identification and mapping of single nucleotide polymorphisms in the human genome |
WO2006043354A1 (ja) * | 2004-10-20 | 2006-04-27 | National Institute Of Radiological Sciences | 組込型の低線量放射線誘導性ベクター |
EP3119798B1 (en) * | 2014-03-17 | 2020-08-05 | Adverum Biotechnologies, Inc. | Compositions and methods for enhanced gene expression in cone cells |
MA41346A (fr) * | 2015-01-12 | 2017-11-21 | Juno Therapeutics Inc | Eléments régulateurs post-transcriptionnels d'hépatite modifiée |
EP3210632B1 (en) * | 2016-02-23 | 2022-09-28 | EyeServ GmbH | Gene therapy for the treatment of a retinal degeneration disease |
KR20230039779A (ko) | 2016-07-29 | 2023-03-21 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 변이체 캡시드를 갖는 아데노-관련된 바이러스 비리온 및 이의 사용 방법 |
EP3720460A1 (en) * | 2017-12-05 | 2020-10-14 | University of Washington | Compositions and methods for enhancing functional expression of therapeutic genes in photoreceptors |
KR20220108096A (ko) * | 2019-11-29 | 2022-08-02 | 파로스 바이오, 인코포레이티드 | 신경퇴행성 질환에 대한 유전자 요법 |
-
2022
- 2022-05-18 UY UY0001039772A patent/UY39772A/es unknown
- 2022-05-18 US US17/747,881 patent/US20230049217A1/en active Pending
- 2022-05-19 AU AU2022278028A patent/AU2022278028A1/en active Pending
- 2022-05-19 WO PCT/IB2022/054650 patent/WO2022243913A1/en active Application Filing
- 2022-05-19 IL IL308027A patent/IL308027A/en unknown
- 2022-05-19 PE PE2023003082A patent/PE20240137A1/es unknown
- 2022-05-19 CR CR20230599A patent/CR20230599A/es unknown
- 2022-05-19 TW TW111118711A patent/TW202313981A/zh unknown
- 2022-05-19 JP JP2023571759A patent/JP2024522072A/ja active Pending
- 2022-05-19 CA CA3218689A patent/CA3218689A1/en active Pending
- 2022-05-19 EP EP22727448.7A patent/EP4341412A1/en active Pending
- 2022-05-19 KR KR1020237043720A patent/KR20240010489A/ko unknown
-
2023
- 2023-11-16 DO DO2023000255A patent/DOP2023000255A/es unknown
- 2023-12-19 EC ECSENADI202395204A patent/ECSP23095204A/es unknown
- 2023-12-19 CO CONC2023/0017779A patent/CO2023017779A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
EP4341412A1 (en) | 2024-03-27 |
CA3218689A1 (en) | 2022-11-24 |
IL308027A (en) | 2023-12-01 |
CR20230599A (es) | 2024-01-25 |
WO2022243913A1 (en) | 2022-11-24 |
CO2023017779A2 (es) | 2024-01-15 |
JP2024522072A (ja) | 2024-06-11 |
US20230049217A1 (en) | 2023-02-16 |
AU2022278028A1 (en) | 2023-11-09 |
AU2022278028A9 (en) | 2023-11-16 |
DOP2023000255A (es) | 2023-12-29 |
TW202313981A (zh) | 2023-04-01 |
PE20240137A1 (es) | 2024-01-30 |
UY39772A (es) | 2023-01-31 |
KR20240010489A (ko) | 2024-01-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2018003196A1 (es) | Cápsides variantes de virus adenoasociados y métodos de uso de estas. | |
BR112019001815A2 (pt) | vírions do vírus adeno-associado com capsídeo variante e seus métodos de uso | |
CO2020004738A2 (es) | Variantes de cápsides de virus adenoasociados y métodos de uso de estas | |
CL2020001360A1 (es) | Cápsides variantes de virus adenoasociados y su uso para inhibir la angiogénesis. | |
AR118734A1 (es) | Formulaciones y métodos de vectores de virus adenoasociados | |
CL2016002840A1 (es) | Composiciones que comprenden aav que expresa constructos de anticuerpos duales y sus usos | |
CO2020002674A2 (es) | Moléculas de ácido nucleico y sus usos | |
BR112019009113A2 (pt) | formulações de vírus adenoassociado | |
AR093578A1 (es) | Metodos para la elaboracion de polipeptidos procesados proteoliticamente | |
BR112013027120A2 (pt) | vírions de vírus adenoassociado com capsídeo variante e métodos de uso dos mesmos | |
CO2020001930A2 (es) | Adenovirus armado con captador biespecífico de linfocitos t (bite) | |
CO2021016323A2 (es) | Composiciones útiles en el tratamiento de leucodistrofia metacromática | |
CO2020015167A2 (es) | Variante de antígeno de virus de varicela zóster y uso de la misma | |
BR112012026730A8 (pt) | vetor viral adeno-associado recombinante, vírion, pluralidade de partículas virais infecciosas, célula hospedeira de mamífero, kit, uso de composição, métodos para prevenir, tratar ou melhorar doença, disfunção, distúrbio, deficiência ou condição anormal em mamífero de um ou mais sintomas dos mesmos, para prover quantidade terapeuticamente eficaz de peptídeo, polipeptídeo ou proteína de guanilato ciclase a mamífero biologicamente ativo em necessidade da mesma, para aumentar o nível de proteína retgc1 biologicamente ativa em uma ou mais células retinais de mamífero e para tratar ou melhorar um ou mais sintomas de distrofia retinal em mamífero | |
MX2020004643A (es) | Composiciones y metodos para mejorar la funcion visual. | |
BR112018068342A2 (pt) | vacina de vírus zika vivo atenuado | |
BR112021015751A2 (pt) | Vetores de terapia genética para tratamento da doença de danon | |
CL2009001249A1 (es) | Uso de una enzima pectonilitica endopoligalacturonasa para tratar pure de frutas o verduras; procedimiento para tratamiento enzimatico; molecula de adn que codifica un polipeptido con actividad endopoligalacturonasa; polipeptido, vector de expresion y celula huesped que comprende dicha secuencia. | |
CO2022016956A2 (es) | Composiciones útiles en el tratamiento del trastorno de deficiencia de cdkl5 (cdd) | |
CO2021012074A2 (es) | Suministro de β-sarcoglicano mediante vectores de virus adenoasociado y el tratamiento de la distrofia muscular | |
ECSP23095204A (es) | Composiciones y métodos para mejorar la función visual | |
BR112021024855A2 (pt) | Composições de vírus adenoassociados para transferência de gene arsa e métodos de uso das mesmas | |
CL2020001358A1 (es) | Cepa vacunal de brucella modificada para el tratamiento de brucelosis | |
MX2020004833A (es) | Un poliepitopo quimerico del virus del zika que comprende proteinas no estructurales y su uso en una composicion inmunogenica. | |
BR112022023545A2 (pt) | Polipeptídeo com atividade de cisteína protease de igg, polinucleotídeo, vetor de expressão, célula hospedeira, composição e métodos para a prevenção ou tratamento de uma doença ou condição e para a clivagem de igg ex vivo |